Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia - ScienceDirect
PCYC 2014.12.31 - 10-K
Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study | springermedizin.de
PDF) Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib
On the architecture of translational research designed to control chronic lymphocytic leukemia
PDF) Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib
Evolving Strategies for the Treatment of Chronic Lymphocytic Leukemia in the Upfront Setting | SpringerLink
régi Átlátni Szellőztetés pcyc 1130 illuminate trial presentation overall survival nacionalizmus körte Kábító
New Paradigms in the Treatment of Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia and Chronic
Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia
PCYC 2014.12.31 - 10-K
Frontiers | Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?
Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study | SpringerLink
New Paradigms in the Treatment of Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia and Chronic
Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study | springermedizin.de
PDF) Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib
Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study | springermedizin.de
JANSSEN | Business Wire
régi Átlátni Szellőztetés pcyc 1130 illuminate trial presentation overall survival nacionalizmus körte Kábító
Cancer patient survival can be parametrized to improve trial precision and reveal time-dependent therapeutic effects | Nature Communications
Cancers | Free Full-Text | Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell Lymphomas
PDF) Long‐term efficacy of first‐line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials
PDF) Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia
Presentazione di PowerPoint
iLLUMINATE - Progression-Free Survival | IMBRUVICA® (ibrutinib) HCP
